These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 20686260)

  • 1. Novel acyl-CoA: cholesterol acyltransferase inhibitor: indoline-based sulfamide derivatives with low lipophilicity and protein binding ratio.
    Takahashi K; Ohta M; Shoji Y; Kasai M; Kunishiro K; Miike T; Kanda M; Shirahase H
    Chem Pharm Bull (Tokyo); 2010 Aug; 58(8):1057-65. PubMed ID: 20686260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel indoline-based acyl-CoA: cholesterol acyltransferase inhibitor: Effects of introducing a methanesulfonamide group on physicochemical properties and biological activities.
    Shoji Y; Takahashi K; Ohta M; Kasai M; Kunishiro K; Kanda M; Yogai S; Takeuchi Y; Shirahase H
    Bioorg Med Chem; 2009 Aug; 17(16):6020-31. PubMed ID: 19608421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel tetrahydroisoquinoline derivatives with inhibitory activities against acyl-CoA: cholesterol acyltransferase and lipid peroxidation.
    Ohta M; Takahashi K; Kasai M; Shoji Y; Kunishiro K; Miike T; Kanda M; Mukai C; Shirahase H
    Chem Pharm Bull (Tokyo); 2010 Aug; 58(8):1066-76. PubMed ID: 20686261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel indoline-based acyl-CoA:cholesterol acyltransferase inhibitor with antiperoxidative activity: improvement of physicochemical properties and biological activities by introduction of carboxylic acid.
    Takahashi K; Kasai M; Ohta M; Shoji Y; Kunishiro K; Kanda M; Kurahashi K; Shirahase H
    J Med Chem; 2008 Aug; 51(15):4823-33. PubMed ID: 18620381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationships between lipophilicity and biological activities in a series of indoline-based anti-oxidative acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors.
    Takahashi K; Kunishiro K; Kasai M; Miike T; Kurahashi K; Shirahase H
    Arzneimittelforschung; 2008; 58(12):666-72. PubMed ID: 19202739
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Importance of acyl-coenzyme A:cholesterol acyltransferase 1/2 dual inhibition for anti-atherosclerotic potency of pactimibe.
    Kitayama K; Tanimoto T; Koga T; Terasaka N; Fujioka T; Inaba T
    Eur J Pharmacol; 2006 Jul; 540(1-3):121-30. PubMed ID: 16730694
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibitors of acyl-CoA:cholesterol O-acyltransferase (ACAT) as hypocholesterolemic agents: synthesis and structure-activity relationships of novel series of sulfonamides, acylphosphonamides and acylphosphoramidates.
    Lee HT; Roark WH; Picard JA; Sliskovic DR; Roth BD; Stanfield RL; Hamelehle KL; Bousley RF; Krause BR
    Bioorg Med Chem Lett; 1998 Feb; 8(3):289-94. PubMed ID: 9871672
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-atherosclerotic effect of E5324, an inhibitor of acyl-CoA:cholesterol acyltransferase, in Watanabe heritable hyperlipidemic rabbits.
    Kogushi M; Tanaka H; Ohtsuka I; Yamada T; Kobayashi H; Saeki T; Takada M; Hiyoshi H; Yanagimachi M; Kimura T; Yoshitake S; Saito I
    Atherosclerosis; 1996 Aug; 124(2):203-10. PubMed ID: 8830933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pactimibe stabilizes atherosclerotic plaque through macrophage acyl-CoA:cholesterol acyltransferase inhibition in WHHL rabbits.
    Kitayama K; Koga T; Maeda N; Inaba T; Fujioka T
    Eur J Pharmacol; 2006 Jun; 539(1-2):81-8. PubMed ID: 16690054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bioavailable acyl-CoA: cholesterol acyltransferase inhibitor with anti-peroxidative activity: synthesis and biological activity of novel indolinyl amide and urea derivatives.
    Kamiya S; Shirahase H; Yoshimi A; Nakamura S; Kanda M; Matsui H; Kasai M; Takahashi K; Kurahashi K
    Chem Pharm Bull (Tokyo); 2000 Jun; 48(6):817-27. PubMed ID: 10866142
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potent inhibitors of acyl-CoA:cholesterol acyltransferase. 2. Structure-activity relationships of novel N-(2,2-dimethyl-2,3-dihydrobenzofuran-7-yl)amides.
    Kataoka K; Shiota T; Takeyasu T; Minoshima T; Watanabe K; Tanaka H; Mochizuki T; Taneda K; Ota M; Tanabe H; Yamaguchi H
    J Med Chem; 1996 Mar; 39(6):1262-70. PubMed ID: 8632433
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of acyl-CoA:cholesterol O-acyltransferase. synthesis and pharmacological activity of (+/-)-2-dodecyl-alpha-phenyl-N-(2,4,6-trimethoxyphenyl)-2H-tetrazole-5- acetamide and structurally related tetrazole amide derivatives.
    O'Brien PM; Sliskovic DR; Picard JA; Lee HT; Purchase CF; Roth BD; White AD; Anderson M; Mueller SB; Bocan T; Bousley R; Hamelehle KL; Homan R; Lee P; Krause BR; Reindel JF; Stanfield RL; Turluck D
    J Med Chem; 1996 Jun; 39(12):2354-66. PubMed ID: 8691430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple mechanisms of hypocholesterolemic action of pactimibe, a novel acyl-coenzyme A:cholesterol acyltransferase inhibitor.
    Kitayama K; Koga T; Inaba T; Fujioka T
    Eur J Pharmacol; 2006 Aug; 543(1-3):123-32. PubMed ID: 16814766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypolipidemic and antioxidant activity of the novel acyl-CoA:cholesterol acyltransferase (ACAT) inhibitor KY-455 in rabbits and hamsters.
    Nakamura S; Kamiya S; Shirahase H; Kanda M; Yoshimi A; Tarumi T; Kurahashi K
    Arzneimittelforschung; 2004; 54(2):102-8. PubMed ID: 15038459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial.
    Meuwese MC; de Groot E; Duivenvoorden R; Trip MD; Ose L; Maritz FJ; Basart DC; Kastelein JJ; Habib R; Davidson MH; Zwinderman AH; Schwocho LR; Stein EA;
    JAMA; 2009 Mar; 301(11):1131-9. PubMed ID: 19293413
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of membrane environment on inhibition of acyl-CoA:cholesterol acyltransferase by a range of synthetic inhibitors.
    Harte RA; Yeaman SJ; Jackson B; Suckling KE
    Biochim Biophys Acta; 1995 Oct; 1258(3):241-50. PubMed ID: 7548193
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitors of acyl-CoA:cholesterol O-acyltransferase. 2. Identification and structure-activity relationships of a novel series of N-alkyl-N-(heteroaryl-substituted benzyl)-N'-arylureas.
    Tanaka A; Terasawa T; Hagihara H; Sakuma Y; Ishibe N; Sawada M; Takasugi H; Tanaka H
    J Med Chem; 1998 Jun; 41(13):2390-410. PubMed ID: 9632372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study.
    Nicholls SJ; Sipahi I; Schoenhagen P; Wisniewski L; Churchill T; Crowe T; Goormastic M; Wolski K; Tuzcu EM; Nissen SE;
    Am Heart J; 2006 Jul; 152(1):67-74. PubMed ID: 16824833
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First identification of xanthone sulfonamides as potent acyl-CoA:cholesterol acyltransferase (ACAT) inhibitors.
    Hu H; Liao H; Zhang J; Wu W; Yan J; Yan Y; Zhao Q; Zou Y; Chai X; Yu S; Wu Q
    Bioorg Med Chem Lett; 2010 May; 20(10):3094-7. PubMed ID: 20403694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis and structure-activity relationship of pyripyropene A derivatives as potent and selective acyl-CoA:cholesterol acyltransferase 2 (ACAT2) inhibitors: part 2.
    Ohtawa M; Yamazaki H; Matsuda D; Ohshiro T; Rudel LL; Ōmura S; Tomoda H; Nagamitsu T
    Bioorg Med Chem Lett; 2013 May; 23(9):2659-62. PubMed ID: 23535327
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.